Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BP-4961
- Development stage
- Unknown
- Lead developer
- 3B Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
3BP-4961 (SPECTROFAP) is a radiopharmaceutical imaging agent developed by 3B Pharmaceuticals for the detection and characterization of tumors expressing Fibroblast Activation Protein (FAP). FAP is a cell surface protease that is highly upregulated on cancer-associated fibroblasts (CAFs) within the stroma of most solid tumors, while remaining largely absent in healthy adult tissues. 3BP-4961 is a peptide-based ligand designed to bind with high affinity to FAP. When labeled with the radioisotope Technetium-99m (99mTc), it serves as a tracer for Single Photon Emission Computed Tomography (SPECT) imaging, allowing for the non-invasive visualization of the tumor microenvironment. The agent is currently in Phase 1 clinical development for use in patients with FAP-expressing tumors.
- Brand names
- SPECTROFAP
- Other names
- 3BP-4961 (99mTc)[99mTc]Tc-3BP-4961SPECTROFAP (99mTc)
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 3BP-4961.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BP-4961.